Question

Which among the following statement is correct with respect to their mechanism of action?

• A. Sitagliptin/Vildagliptin : Dipeptidyl peptidase-4 inhibitors
• B. Dapagliflozine/Canaglifozine : AMPk activators
• C. Glibenclamide/ Glimepiride : a-Glucosidase inhibitors
• D. Acarose/Metformin : KATP channel blockers

Answer 1

The Correct Option is A

The question asks us to identify the correct statement based on the mechanism of action of various drug groups. Let's analyze each option one by one to determine which is correct:

1. Sitagliptin/Vildagliptin: Dipeptidyl peptidase-4 inhibitors
   These drugs belong to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 is an enzyme that breaks down incretin hormones, which are responsible for the regulation of insulin. By inhibiting DPP-4, these drugs increase the levels of incretins and thereby improve insulin secretion and lower blood glucose levels. This statement is correct.
2. Dapagliflozine/Canaglifozine: AMPk activators
   Dapagliflozin and Canagliflozin are actually sodium-glucose cotransporter 2 (SGLT2) inhibitors. They work by preventing the reabsorption of glucose in the kidneys, thus lowering blood sugar levels. They are not AMPk activators. This statement is incorrect.
3. Glibenclamide/Glimepiride: a-Glucosidase inhibitors
   Glibenclamide (Glyburide) and Glimepiride are sulfonylureas. They work by stimulating insulin secretion from the pancreatic beta cells. These drugs are not a-glucosidase inhibitors, which act by delaying the absorption of carbohydrates from the intestines. This statement is incorrect.
4. Acarbose/Metformin: K_ATP channel blockers
   Acarbose is an a-glucosidase inhibitor that helps to slow down the digestion of carbohydrates. Metformin reduces glucose production by the liver and increases insulin sensitivity, but it does not act as a K_ATP channel blocker. This statement is incorrect.

From the above analysis, the correct statement based on the mechanism of action is Sitagliptin/Vildagliptin: Dipeptidyl peptidase-4 inhibitors.